Sight Sciences, Inc. (NASDAQ:SGHT) Shares Purchased by Jackson Square Partners LLC

Jackson Square Partners LLC raised its stake in Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) by 12.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,629,746 shares of the company's stock after purchasing an additional 174,737 shares during the quarter. Jackson Square Partners LLC owned about 3.34% of Sight Sciences worth $8,409,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in SGHT. Boston Partners lifted its holdings in Sight Sciences by 3.1% during the 3rd quarter. Boston Partners now owns 331,776 shares of the company's stock worth $1,117,000 after buying an additional 9,919 shares during the last quarter. Swiss National Bank increased its holdings in shares of Sight Sciences by 19.5% in the third quarter. Swiss National Bank now owns 69,314 shares of the company's stock valued at $234,000 after buying an additional 11,300 shares in the last quarter. First Eagle Investment Management LLC increased its stake in Sight Sciences by 45.6% in the 3rd quarter. First Eagle Investment Management LLC now owns 587,297 shares of the company's stock worth $1,979,000 after purchasing an additional 183,912 shares in the last quarter. Federated Hermes Inc. raised its holdings in shares of Sight Sciences by 100.0% during the third quarter. Federated Hermes Inc. now owns 60,000 shares of the company's stock valued at $202,000 after acquiring an additional 30,000 shares during the period. Finally, Panagora Asset Management Inc. lifted its holdings in shares of Sight Sciences by 198.1% in the fourth quarter. Panagora Asset Management Inc. now owns 59,190 shares of the company's stock valued at $305,000 after purchasing an additional 39,333 shares in the last quarter. Hedge funds and other institutional investors own 55.51% of the company's stock.

Insider Activity

In other Sight Sciences news, CEO Paul Badawi sold 12,571 shares of the business's stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total transaction of $63,860.68. Following the completion of the sale, the chief executive officer now directly owns 5,750,729 shares of the company's stock, valued at approximately $29,213,703.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Sight Sciences news, CFO Alison Bauerlein sold 10,123 shares of the company's stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total value of $51,424.84. Following the completion of the transaction, the chief financial officer now owns 426,248 shares in the company, valued at approximately $2,165,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Paul Badawi sold 12,571 shares of the firm's stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total transaction of $63,860.68. Following the sale, the chief executive officer now owns 5,750,729 shares of the company's stock, valued at approximately $29,213,703.32. The disclosure for this sale can be found here. Insiders sold a total of 34,129 shares of company stock worth $173,375 over the last quarter. 27.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on SGHT shares. Needham & Company LLC restated a "hold" rating on shares of Sight Sciences in a report on Friday, May 3rd. Piper Sandler restated a "neutral" rating and issued a $6.00 price objective (up previously from $5.00) on shares of Sight Sciences in a research note on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $4.70.

Sight Sciences Stock Performance

Shares of SGHT stock traded down $0.47 during midday trading on Friday, hitting $5.34. 167,183 shares of the company were exchanged, compared to its average volume of 134,768. Sight Sciences, Inc. has a 52 week low of $1.04 and a 52 week high of $10.69. The company has a debt-to-equity ratio of 0.31, a quick ratio of 12.42 and a current ratio of 13.01. The firm's 50 day moving average price is $5.34 and its two-hundred day moving average price is $4.38. The firm has a market capitalization of $265.72 million, a P/E ratio of -4.77 and a beta of 2.73.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its earnings results on Thursday, March 7th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.13. Sight Sciences had a negative net margin of 67.18% and a negative return on equity of 44.45%. The firm had revenue of $18.75 million during the quarter, compared to analysts' expectations of $18.70 million. During the same quarter in the prior year, the business earned ($0.35) earnings per share. As a group, equities research analysts anticipate that Sight Sciences, Inc. will post -1.13 earnings per share for the current year.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.